Turim 21 Investimentos’s Regeneron Pharmaceuticals REGN Stock Holding History

Turim 21 Investimentos’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100	Closed	-$52.5K	–	135
2025 Q2	$52.5K	Hold	100	–	–	0.01%	51
2025 Q1	$63.4K	Hold	100	–	–	0.02%	42
2024 Q4	$67.3K	Hold	100	–	–	0.02%	46
2024 Q3	$105K	Hold	100	–	–	0.03%	36
2024 Q2	$105K	Hold	100	–	–	0.03%	33
2024 Q1	$96.2K	Hold	100	–	–	0.02%	33
2023 Q4	$87.8K	Hold	100	–	–	0.03%	42
2023 Q3	$82.3K	Hold	100	–	–	0.04%	37
2023 Q2	$71.9K	Hold	100	–	–	0.04%	44
2023 Q1	$82.2K	Hold	100	–	–	0.08%	30
2022 Q4	$72.1K	Hold	100	–	–	0.04%	32
2022 Q3	$69K	Hold	100	–	–	0.06%	36
2022 Q2	$59K	Hold	100	–	–	0.05%	53
2022 Q1	$70K	Hold	100	–	–	0.03%	66
2021 Q4	$63K	Hold	100	–	–	0.03%	52
2021 Q3	$61K	Hold	100	–	–	0.03%	52
2021 Q2	$56K	Buy	+100	New	+$50.7K	0.02%	67

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Turim 21 Investimentos's REGN Position: Q3 2025 in Review

Turim 21 Investimentos sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 100 shares — an estimated $52.5K sold.

Turim 21 Investimentos first reported a position in REGN in Q2 2021 and held it in 17 quarters. The position peaked at $105K in Q3 2024. 1,246 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Turim 21 Investimentos reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Turim 21 Investimentos sold 100 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $52.5K.
Turim 21 Investimentos first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 17 quarters.
Turim 21 Investimentos's Regeneron Pharmaceuticals position peaked at $105K in Q3 2024.
1,246 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Turim 21 Investimentos's 13F filing for Q3 2025, filed 14 Nov 2025.